Chronic Renal Failure, Hemodialysis
Conditions
Keywords
hemodialysis, beta microglobulin, amyloidosis
Brief summary
The site where the clinical trial will be conducted is at the St-Luc hospital from the CHUM. This is a prospective randomized study that will compare the two treatment modalities, HD and HDF, through economics and pharmaco-economics parameters. Patients, who had previously been randomized in the CONTRAST study, will remain in their respective group and monitoring will continue. The next patients will be randomized in the same way (1: 1) using the same inclusion and exclusion criteria. HDF randomized patients will receive post-dilution standard reinjection (at least 100ml/min or 6 liter/hr). In rare cases, HDF patients can briefly have reinjection on a pre-dilution mode (if heparin need to be avoided for example) and the reinjection flow should be adjusted accordingly (200ml/min). Length and frequency of sessions will be the same in the 2 groups. Blood tests will not change and will be the same than those used as routine assessments. Metabolic control of patients will be maintained according to the guidelines. Patients will be monitored for a minimum of 3 years. A set of demographic and clinical data will be collected from patient medical records and throughout the study. Biochemical data as part of the usual blood tests of dialysis patients will be collected each month as well as will be stored and analyzed information about the annual cardiac ultrasounds. All events will be scored (hospitalizations, patterns, duration) and the list and cost of drugs will be compiled every three months. These data will be useful in the economic analysis comparing the two treatment modalities.
Interventions
DEVICEhemodiafiltration On-line
Sponsors
Centre hospitalier de l'Université de Montréal (CHUM)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* more than 18 years old, * able to consent, * patient needs to be on hemodialysis more than 8-12 hours a week (2-3 sessions)
Exclusion criteria
* severe none compliance (often missing sessions without good reasons), * life expectation less than 3 months, * treated with high-flux filters in the last 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| compare the medication cost between the 2 groups (HD and HDF) | 3 years |
| demonstrate lower cost of erythropoietin in HDF, with same control of anemia to HD group | 3 years |
| demonstrate lower cost of phosphate binder in HDF, with same control of phospho calcium balance to HD group | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| demonstrate lower need of Erythropoietin and best control of anemia in HDF | 3 years |
| stabilisation or regression of left ventricular hypertrophy | 3 years |
| demonstrate lower need of phosphate binder and best control of phospho-calcique balance in HDF | 3 years |
| demonstrate less hospitalization stay and cost related in HDF group | 3 years |
Countries
Canada
Outcome results
None listed